FFO
LYRA

Fortitude Family Office’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Fortitude Family Office’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-96
Closed -$627 – 2039
2025
Q3 		$627 Buy
+96
New +$704 ﹤0.01% 1720

Other funds holding LYRA

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $499M AUM 186.05% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

Fortitude Family Office's LYRA Position: Q4 2025 in Review

Fortitude Family Office sold out of LYRA THERAPEUTICS INC (LYRA) in Q4 2025, closing a stake of 96 shares — an estimated $627 sold.

Fortitude Family Office first reported a position in LYRA in Q3 2025 and held it in 1 quarter. The position peaked at $627 in Q3 2025. 23 funds tracked by Wall St. Rank hold LYRA as of Q4 2025.

  • Fortitude Family Office reported no remaining LYRA THERAPEUTICS INC position as of Q4 2025 after selling out during the quarter.
  • Fortitude Family Office sold 96 LYRA THERAPEUTICS INC shares in Q4 2025, an estimated $627.
  • Fortitude Family Office first reported a position in LYRA THERAPEUTICS INC in Q3 2025 and held it in 1 quarter.
  • Fortitude Family Office's LYRA THERAPEUTICS INC position peaked at $627 in Q3 2025.
  • 23 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q4 2025.

Based on Fortitude Family Office's 13F filing for Q4 2025, filed 15 Jan 2026.